查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1771542

血友病市场规模、份额、趋势分析报告：按疾病类型、治疗类型、治疗方法、分销管道、地区和细分市场进行预测，2025 年至 2030 年

Hemophilia Market Size, Share & Trends Analysis Report By Type (Hemophilia A, Hemophilia B), By Treatment Type (On-demand, Cure), By Therapy, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 110 Pages | 商品交期: 2-10个工作天内

价格

血友病市场的成长与趋势：

根据Grand View Research, Inc.的最新报告，全球血友病市场规模预计到2030年将达到210.7亿美元，2025年至2030年的复合年增长率为6.91%。

用于治疗血友病的基因疗法和单株抗体的核准以及正在研发的几种此类候选药物是市场成长的主要驱动力，同时由于死亡率下降，血友病患者的预期平均寿命也在增加。

控制血友病的新型疗法的开发和上市正在推动市场成长。例如，2020年4月，美国食品药物管理局（FDA）核准了基因工程产品Sevenfact [凝血因子VIIa（重组）-jncw]，作为控制青少年（12岁及以上）和成年人出血发作的治疗选择。此外，BioMarin的A型血友病A治疗药物Roctavian仅在欧洲核准，而CSL的Hemgenix（etranacogene dezaparvovec-drib）在美国和欧洲都核准。 BioMarin的Roctavian先前被美国食品药物管理局（FDA）驳回，目前正在接受审查，其PDUFA（处方药使用者付费法案）的截止日期为2023年6月30日。

大型公司正专注于新产品开发和策略联盟，以扩大其地理影响力。例如，2022年4月，诺和诺德公司与加拿大血液服务中心合作，增强了其Esperoct和Zonovate的产品阵容，这两款产品均作为治疗甲型血友病的药物上市。此外，2023年2月，赛诺菲公司获得美国食品药物管理局（FDA）核准其用于治疗A型血友病。

然而，在中国和印度等新兴国家，轻度至中度病例的诊断延迟是一个重大阻碍因素。市场面临的另一个重大挑战是，由于高成本且缺乏长期数据，基因治疗的可近性可能存在问题。例如，HemGenics 公司的疗法（于 2022 年核准）每剂售价高达 350 万美元，是全球最昂贵的治疗方法。

血友病市场报告重点

  • 由于A型血友病的A型血友病A型血友病将在2024年占据血友病市场的最大份额。由于基因疗法的核准，该细分市场预计在预测期内也将实现最高的复合年增长率。
  • 根据销售管道，由于该疾病需要专门的治疗，预计专业药局将在 2024 年占据最大的市场占有率。
  • 根据治疗方法，因子替代疗法在 2024 年占据血友病市场的最大份额，因为它是用于预防和按需治疗的主要治疗方法。
  • 由于主要企业的存在、监管支持、患者意识和有利的资金支持，北美将成为 2024 年血友病市场收益最高的地区。

目录

第一章调查方法与范围

第二章执行摘要

3. 血友病市场变数、趋势和范围

  • 市场展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 血友病市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
  • 管道分析

第四章血友病市场：疾病类型估计与趋势分析

  • 2024 年及 2030 年疾病类型市场占有率
  • 细分仪表板
  • 全球血友病市场：疾病类型展望
  • 2018-2030年市场规模、预测与趋势分析
    • A型血友病A
    • B型血友病
    • 其他的

第五章血友病市场：治疗类型估计与趋势分析

  • 2024 年和 2030 年治疗类型市场占有率
  • 细分仪表板
  • 全球血友病市场按治疗类型展望
  • 2018-2030年市场规模、预测与趋势分析
    • 一经请求
    • 治疗
    • 预防

第六章血友病市场：治疗方法评估与趋势分析

  • 2024 年和 2030 年治疗方法市场占有率
  • 细分仪表板
  • 全球血友病市场：治疗方法展望
  • 2018-2030年市场规模、预测与趋势分析
    • 因子替代疗法
    • 去氨加压素和纤维蛋白胶
    • 基因治疗和单株抗体

第七章血友病市场：通路评估与趋势分析

  • 2024年及2030年分销通路市场占有率
  • 细分仪表板
  • 全球血友病市场（按分销管道）
  • 2018-2030年市场规模、预测与趋势分析
    • 医院药房
    • 专业药房

第八章血友病市场：区域估计与趋势分析

  • 2024 年及 2030 年区域市场占有率分析
  • 细分仪表板
  • 全球区域市场概况
  • 2018-2030年市场规模、预测趋势分析
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第九章 竞争态势

  • 主要市场参与企业的近期趋势和影响分析
  • 公司/竞争对手分类
  • 供应商格局
    • 主要经销商和通路合作伙伴名单
    • Key customers
    • Key company market share analysis, 2024
    • Takeda Pharmaceutical Company Limited.
    • CSL Behring
    • Pfizer Inc.
    • Bayer AG
    • BioMarin
    • Spark Therapeutics, Inc.
    • Sanofi
    • F. Hoffmann La-Roche Ltd
    • Novo Nordisk A/S
    • Octapharma AG.
Product Code: 978-1-68038-989-0

Hemophilia Market Growth & Trends:

The global hemophilia market size is estimated to reach USD 21.07 billion by 2030, registering a CAGR of 6.91% from 2025 to 2030, according to a new report by Grand View Research, Inc. The approval of gene therapy and monoclonal antibodies for treating hemophilia and the presence of multiple such candidates in the pipeline are major drivers for market growth. In addition, the increasing life expectancy of hemophilia patients due to reduced mortality is another key factor driving market growth.

The development and launch of novel therapies to control hemophilia are propelling the market growth. For instance, in April 2020, FDA approved the genetically engineered product Sevenfact [coagulation factor VIIa (recombinant)-jncw] as a treatment option to control bleeding episodes in adolescents (of age group 12 years and above) and adults. Furthermore, the presence of 2 gene therapy products, BioMarin's Roctavian for hemophilia A, was approved only in Europe, and CSL's Hemgenix (etranacogene dezaparvovec-drib) was approved both in the U.S., and Europe demonstrates an opportunity for expansion in other regions. BioMarin's Roctavian is under review with the U.S. FDA after its previous rejection and has a PDUFA date set for June 30, 2023.

Major players are focused on developing new products and entering into strategic collaborations for enhanced geographic presence. For instance, in April 2022, Novo Nordisk A/S partnered with Canadian Blood Services to enhance its product offering with marketed drugs Esperoct and Zonovate, publicly available for treating type A. Moreover, in February 2023, Sanofi received FDA approval for its drug Altuviiio, a factor VIII replacement therapy for treating hemophilia A.

However, a key restraining factor is the delayed diagnosis of mild to moderate disease in developing countries such as China and India. Another key challenge for the market is the possible access issues for gene therapy due to its high cost and lack of long-term data. For instance, the cost of treatment using Hemgenix (Approved in 2022) is USD 3.5 million per treatment, making it the most expensive treatment in the world.

Hemophilia Market Report Highlights:

  • The type A segment held the largest share of the hemophilia market in 2024, owing to the higher prevalence of hemophilia A and the availability of multiple products for its treatment. This segment is also expected to grow at the highest CAGR during the forecast period owing to the approval of gene therapy.
  • Based on the distribution channel, the specialty pharmacies segment held the largest market share in 2024, attributable to the specialized nature of the treatment required for the condition
  • By therapy, factor replacement therapy held the largest share of the hemophilia market in 2024, as it is the major form of treatment used in both prophylaxis and on-demand treatment.
  • North America was the largest revenue-generating region in the hemophilia market in 2024, which can be attributed to the presence of key players, regulatory support, patient awareness, and favorable funding assistance.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Treatment
    • 1.2.3. Therapy
    • 1.2.4. Distribution Channel
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type
    • 2.2.2. Treatment
    • 2.2.3. Therapy
    • 2.2.4. Distribution Channel
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Hemophilia Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Hemophilia Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
  • 3.4. Pipeline Analysis
      • 3.4.1.1. Phase 1
      • 3.4.1.2. Phase 2
      • 3.4.1.3. Phase 3

Chapter 4. Hemophilia Market: Disease Type Estimates & Trend Analysis

  • 4.1. Type Market Share, 2024 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Hemophilia Market by Type Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 - 2030 for the following
    • 4.4.1. Hemophilia A
      • 4.4.1.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.4.2. Hemophilia B
      • 4.4.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.4.3. Others
      • 4.4.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5. Hemophilia Market: Treatment Type Estimates & Trend Analysis

  • 5.1. Treatment Type Market Share, 2024 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Hemophilia Market by Treatment Type Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 - 2030 for the following
    • 5.4.1. On-demand
      • 5.4.1.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.4.2. Cure
      • 5.4.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.4.3. Prophylaxis
      • 5.4.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. Hemophilia Market: Therapy Estimates & Trend Analysis

  • 6.1. Therapy Market Share, 2024 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Hemophilia Market by Therapy Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 - 2030 for the following
    • 6.4.1. Factor Replacement Therapy
      • 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
      • 6.4.1.2. Plasma derived Factor Concentrates estimates and forecasts, 2018 - 2030 (USD Million)
        • 6.4.1.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
        • 6.4.1.2.2. Factor VIII
          • 6.4.1.2.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
        • 6.4.1.2.3. Factor IX
          • 6.4.1.2.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
      • 6.4.1.3. Recombinant Factor Concentrates
        • 6.4.1.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
          • 6.4.1.3.1.1. Factor VIII
            • 6.4.1.3.1.1.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
          • 6.4.1.3.1.2. Factor VII
            • 6.4.1.3.1.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
          • 6.4.1.3.1.3. Factor IX
            • 6.4.1.3.1.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. Desmopressin & Fibrin sealants
      • 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Gene Therapy & Monoclonal Antibodies
      • 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7. Hemophilia Market: Distribution Channel Estimates & Trend Analysis

  • 7.1. Distribution Channel Market Share, 2024 & 2030
  • 7.2. Segment Dashboard
  • 7.3. Global Hemophilia Market by Gender Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 - 2030 for the following
    • 7.4.1. Hospital Pharmacies
      • 7.4.1.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. Specialty Pharmacies
      • 7.4.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 8. Hemophilia Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2024 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. Market Size, & Forecasts Trend Analysis, 2018 - 2030:
  • 8.5. North America
    • 8.5.1. U.S.
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework/ reimbursement structure
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.5.2. Canada
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. Canada market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.5.3. Mexico
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework/ reimbursement structure
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.6. Europe
    • 8.6.1. UK
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework/ reimbursement structure
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. UK market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.6.2. Germany
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Germany market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. France
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Regulatory framework/ reimbursement structure
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. France market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. Italy
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Regulatory framework/ reimbursement structure
      • 8.6.4.3. Competitive scenario
      • 8.6.4.4. Italy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.6.5. Spain
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Regulatory framework/ reimbursement structure
      • 8.6.5.3. Competitive scenario
      • 8.6.5.4. Spain market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.6.6. Norway
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Regulatory framework/ reimbursement structure
      • 8.6.6.3. Competitive scenario
      • 8.6.6.4. Norway market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.6.7. Sweden
      • 8.6.7.1. Key country dynamics
      • 8.6.7.2. Regulatory framework/ reimbursement structure
      • 8.6.7.3. Competitive scenario
      • 8.6.7.4. Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.6.8. Denmark
      • 8.6.8.1. Key country dynamics
      • 8.6.8.2. Regulatory framework/ reimbursement structure
      • 8.6.8.3. Competitive scenario
      • 8.6.8.4. Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.7. Asia Pacific
    • 8.7.1. Japan
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework/ reimbursement structure
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. Japan market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.7.2. China
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. China market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.7.3. India
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/ reimbursement structure
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. India market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.7.4. Australia
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/ reimbursement structure
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Australia market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.7.5. South Korea
      • 8.7.5.1. Key country dynamics
      • 8.7.5.2. Regulatory framework/ reimbursement structure
      • 8.7.5.3. Competitive scenario
      • 8.7.5.4. South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.7.6. Thailand
      • 8.7.6.1. Key country dynamics
      • 8.7.6.2. Regulatory framework/ reimbursement structure
      • 8.7.6.3. Competitive scenario
      • 8.7.6.4. Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.8. Latin America
    • 8.8.1. Brazil
      • 8.8.1.1. Key country dynamics
      • 8.8.1.2. Regulatory framework/ reimbursement structure
      • 8.8.1.3. Competitive scenario
      • 8.8.1.4. Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.8.2. Argentina
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Regulatory framework/ reimbursement structure
      • 8.8.2.3. Competitive scenario
      • 8.8.2.4. Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.9. MEA
    • 8.9.1. South Africa
      • 8.9.1.1. Key country dynamics
      • 8.9.1.2. Regulatory framework/ reimbursement structure
      • 8.9.1.3. Competitive scenario
      • 8.9.1.4. South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.9.2. Saudi Arabia
      • 8.9.2.1. Key country dynamics
      • 8.9.2.2. Regulatory framework/ reimbursement structure
      • 8.9.2.3. Competitive scenario
      • 8.9.2.4. Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.9.3. UAE
      • 8.9.3.1. Key country dynamics
      • 8.9.3.2. Regulatory framework/ reimbursement structure
      • 8.9.3.3. Competitive scenario
      • 8.9.3.4. UAE market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.9.4. Kuwait
      • 8.9.4.1. Key country dynamics
      • 8.9.4.2. Regulatory framework/ reimbursement structure
      • 8.9.4.3. Competitive scenario
      • 8.9.4.4. Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. List of key distributors and channel partners
    • 9.3.2. Key customers
    • 9.3.3. Key company market share analysis, 2024
    • 9.3.4. Takeda Pharmaceutical Company Limited.
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Product benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. CSL Behring
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Product benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. Pfizer Inc.
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Product benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. Bayer AG
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Product benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. BioMarin
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Product benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. Spark Therapeutics, Inc.
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Product benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. Sanofi
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Product benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. F. Hoffmann La-Roche Ltd
      • 9.3.11.1. Company overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Product benchmarking
      • 9.3.11.4. Strategic initiatives
    • 9.3.12. Novo Nordisk A/S
      • 9.3.12.1. Company overview
      • 9.3.12.2. Financial performance
      • 9.3.12.3. Product benchmarking
      • 9.3.12.4. Strategic initiatives
    • 9.3.13. Octapharma AG.
      • 9.3.13.1. Company overview
      • 9.3.13.2. Financial performance
      • 9.3.13.3. Product benchmarking
      • 9.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 Global Hemophilia Market, By Region, 2018 - 2030 (USD Million)
  • Table 3 North America Hemophilia Market, By Country, 2018 - 2030 (USD Million)
  • Table 4 North America Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 5 North America Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 6 North America Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 7 North America Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 8 U.S. Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 9 U.S. Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 10 U.S. Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 11 U.S. Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 12 Canada Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 13 Canada Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 14 Canada Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 15 Canada Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 16 Mexico Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 17 Mexico Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 18 Mexico Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 19 Mexico Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 20 Europe Hemophilia Market, By Country, 2018 - 2030 (USD Million)
  • Table 21 Europe Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 22 Europe Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 23 Europe Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 24 Europe Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 25 UK Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 26 UK Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 27 UK Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 28 UK Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 29 Germany Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 30 Germany Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 31 Germany Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 32 Germany Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 33 France Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 34 France Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 35 France Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 36 France Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 37 Italy Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 38 Italy Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 39 Italy Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 40 Italy Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 41 Spain Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 42 Spain Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 43 Spain Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 44 Spain Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 45 Denmark Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 46 Denmark Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 47 Denmark Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 48 Denmark Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 49 Sweden Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 50 Sweden Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 51 Sweden Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 52 Sweden Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 53 Norway Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 54 Norway Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 55 Norway Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 56 Norway Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific Hemophilia Market, By Country, 2018 - 2030 (USD Million)
  • Table 58 Asia Pacific Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 59 Asia Pacific Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 60 Asia Pacific Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 61 Asia Pacific Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 62 Japan Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 63 Japan Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 64 Japan Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 65 Japan Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 66 China Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 67 China Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 68 China Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 69 China Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 70 India Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 71 India Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 72 India Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 73 India Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 74 South Korea Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 75 South Korea Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 76 South Korea Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 77 South Korea Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 78 Australia Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 79 Australia Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 80 Australia Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 81 Australia Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 82 Thailand Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 83 Thailand Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 84 Thailand Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 85 Thailand Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 86 Latin America Hemophilia Market, By Country, 2018 - 2030 (USD Million)
  • Table 87 Latin America Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 88 Latin America Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 89 Latin America Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 90 Latin America Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 91 Brazil Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 92 Brazil Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 93 Brazil Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 94 Brazil Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 95 Argentina Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 96 Argentina Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 97 Argentina Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 98 Argentina Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 99 MEA Hemophilia Market, By Country, 2018 - 2030 (USD Million)
  • Table 100 MEA Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 101 MEA Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 102 MEA Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 103 MEA Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 104 South Africa Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 105 South Africa Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 106 South Africa Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 107 South Africa Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 108 Saudi Arabia Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 109 Saudi Arabia Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 110 Saudi Arabia Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 111 Saudi Arabia Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 112 UAE Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 113 UAE Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 114 UAE Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 115 UAE Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 116 Kuwait Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 117 Kuwait Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 118 Kuwait Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 119 Kuwait Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Market summary
  • Fig. 4 Market segmentation & scope
  • Fig. 5 Market size and growth prospects
  • Fig. 6 Global hemophilia market- Key market driver analysis
  • Fig. 7 Global hemophilia market - Key market restraint analysis
  • Fig. 8 Penetration & growth prospect mapping
  • Fig. 9 Global hemophilia market - Porter's analysis
  • Fig. 10 Global hemophilia market - PESTEL analysis
  • Fig. 11 Global hemophilia market type outlook key takeaways
  • Fig. 12 Global hemophilia market: Type movement analysis
  • Fig. 13 Hemophilia A market estimates, 2018 - 2030 (USD Million)
  • Fig. 14 Hemophilia B market estimates, 2018 - 2030 (USD Million)
  • Fig. 15 Others market estimates, 2018 - 2030 (USD Million)
  • Fig. 16 Global hemophilia market treatment outlook key takeaways
  • Fig. 17 Global hemophilia market: Treatment Type movement analysis
  • Fig. 18 On-demand market estimates, 2018 - 2030 (USD Million)
  • Fig. 19 Cure market estimates, 2018 - 2030 (USD Million)
  • Fig. 20 Prophylaxis market estimates, 2018 - 2030 (USD Million)
  • Fig. 21 Global hemophilia market therapy outlook key takeaways
  • Fig. 22 Global hemophilia market: Therapy movement analysis
  • Fig. 23 Factor Replacement Therapy market estimates, 2018 - 2030 (USD Million)
  • Fig. 24 Desmopressin & Fibrin sealants market estimates, 2018 - 2030 (USD Million)
  • Fig. 25 Gene Therapy & Monoclonal Antibodies market estimates, 2018 - 2030 (USD Million)
  • Fig. 26 Regional marketplace: Key takeaways
  • Fig. 27 Global hemophilia market: Regional movement analysis
  • Fig. 28 North America hemophilia market, 2018 - 2030 (USD Million)
  • Fig. 29 U.S. hemophilia market, 2018 - 2030 (USD Million)
  • Fig. 30 Canada hemophilia market, 2018 - 2030 (USD Million)
  • Fig. 31 Europe hemophilia market, 2018 - 2030 (USD Million)
  • Fig. 32 UK hemophilia market, 2018 - 2030 (USD Million)
  • Fig. 33 Germany hemophilia market, 2018 - 2030 (USD Million)
  • Fig. 34 France hemophilia market, 2018 - 2030 (USD Million)
  • Fig. 35 Spain hemophilia market, 2018 - 2030 (USD Million)
  • Fig. 36 Italy hemophilia market, 2018 - 2030 (USD Million)
  • Fig. 37 Denmark hemophilia market, 2018 - 2030 (USD Million)
  • Fig. 38 Sweden hemophilia market, 2018 - 2030 (USD Million)
  • Fig. 39 Norway hemophilia market, 2018 - 2030 (USD Million)
  • Fig. 40 Asia Pacific hemophilia market, 2018 - 2030 (USD Million)
  • Fig. 41 Japan hemophilia market, 2018 - 2030 (USD Million)
  • Fig. 42 China hemophilia market, 2018 - 2030 (USD Million)
  • Fig. 43 India hemophilia market, 2018 - 2030 (USD Million)
  • Fig. 44 South Korea hemophilia market, 2018 - 2030 (USD Million)
  • Fig. 45 Australia hemophilia market, 2018 - 2030 (USD Million)
  • Fig. 46 Thailand hemophilia market, 2018 - 2030 (USD Million)
  • Fig. 47 Latin America hemophilia market, 2018 - 2030 (USD Million)
  • Fig. 48 Brazil hemophilia market, 2018 - 2030 (USD Million)
  • Fig. 49 Mexico hemophilia market, 2018 - 2030 (USD Million)
  • Fig. 50 Argentina hemophilia market, 2018 - 2030 (USD Million)
  • Fig. 51 MEA hemophilia market, 2018 - 2030 (USD Million)
  • Fig. 52 South Africa hemophilia market, 2018 - 2030 (USD Million)
  • Fig. 53 Saudi Arabia hemophilia market, 2018 - 2030 (USD Million)
  • Fig. 54 UAE market, 2018 - 2030 (USD Million)
  • Fig. 55 Kuwait market, 2018 - 2030 (USD Million)
  • Fig. 56 Strategy framework